Article
Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR-Mutated Locally Advanced or Metastatic Lung Cancer.
International journal of cancer - 1 Nov 2026
Moiseenko Fedor, Stroyakovskiy Daniil, Levchenko Evgeniy, Fedyanin Mikhail, Gabina Albina, Oganesian Ani, Belukhin Sergey, Stepanova Maria, Stepanova Ekaterina, Artemyeva Elizaveta, Myslik Alexander, Volkov Nikita, Bogdanov Alexei, Shuginova Tatiana, Kryukov Kirill, Kheinshtein Valeria, Allakhverdiev Arif, Zaberegniy Ivan, Akhmadiyarova Yana, Popov Mikhail, Danilova Anastasiya, Sehniaidze Dmitriy, Savelov Nikita, Levchenko Nikita, Slugin Evgeniy, Lopushanskaya Olga, Kuligina Ekaterina, Aleksakhina Svetlana, Iyevleva Aglaya, Ivantsov Alexandr, Moiseyenko Vladimir, Imyanitov Evgeny
Abstract excerpt
Non-small cell lung cancer (NSCLC) patients with EGFR mutations usually receive continuous treatment with tyrosine kinase inhibitors (TKIs) until disease progression. We evaluated whether surgical excision of residual tumor masses offers a survival advantage when performed before progression on TKI therapy. We conducted a retrospective analysis of 230 patients with locally advanced or metastatic EGFR-mutated...
Read the complete abstract on PubMedTopics
- Humans
- ErbB Receptors